SCHEMBL2160647

SCHEMBL2160647

N#Cc1ccc(N)c(C(=O)O)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K3 P46734 2/20 0.38
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
SOS2 Q07890 1/20 0.36
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 4/20 0.35
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 3/20 0.33
GFER P55789 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
PIN1 Q13526 1/20 0.33
CTSB P07858 2/20 0.33
SRC P12931 1/20 0.33
XDH P47989 1/20 0.33
MEN1 O00255 2/20 0.32
THRB P10828 2/20 0.32
USP2 O75604 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31163476 0.80 KDM4E (0.43) MAPTALDH1A1SMN1; SMN2KDM4ERXFP1
SCHEMBL838145 0.79 ALDH1A1 (0.41) SOS2MAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL25010840 0.79 MEN1 (0.42) SOS2MAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL15310084 0.78 PIN1 (0.38) SOS2MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL2160298 0.76 KDM4E (0.47) MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL24679262 0.74 CAMKK2 (0.45) SOS2MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL31660940 0.74 KDM4E (0.44) MAPTALDH1A1TDP1KDM4EXDH
SCHEMBL30168459 0.74 KMT2A (0.37) SOS2MAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL3859925 0.73 ATR (0.39) PTGS1PTGS2ALDH1A1XDHUSP2
SCHEMBL19857475 0.72 KDM4E (0.48) MAP2K3PTGS1PTGS2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023078401-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-11 WO disclosed
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP disclosed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US disclosed
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 US disclosed
WO-2011089132-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES PDE3A, PDE2A, PDE10A MAP2K3 2779/4885PTGS1 311/4885PTGS2 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.